SCHEMBL6007919

SCHEMBL6007919

[NH]CNS(=O)(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
KEAP1 Q14145 2/20 0.61
KDM4E B2RXH2 1/20 0.61
PKM P14618 1/20 0.61
GBA1 P04062 2/20 0.55
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
MAPK1 P28482 1/20 0.50
IL1RN P18510 1/20 0.50
ERAP1 Q9NZ08 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006520 0.83 ALDH1A1 (0.68) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL8349568 0.81 ALDH1A1 (0.79) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL8851809 0.79 ALDH1A1 (0.75) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL5450999 0.79 ALDH1A1 (0.63) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL2573481 0.78 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL7791081 0.78 ALDH1A1 (0.68) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL3651548 0.77 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL301743 0.77 ALDH1A1 (0.67) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL2371761 0.77 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E
SCHEMBL10453840 0.77 ALDH1A1 (0.96) ALDH1A1LMNASMN1; SMN2KEAP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 ALDH1A1 228/4885LMNA 4676/4885SMN1; SMN2 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.